



By Carolyn Gretton

► PHARMACEUTICAL POOL

Dr. Dipak PANIGRAHI

Silvia TAYLOR

SUCAMPO NAMES EXECUTIVES



Global pharmaceutical firm Sucampo Pharmaceuticals has added two VPs to its leadership team.

Sucampo has appointed Dipak Panigrahi, M.D., VP, medical affairs. Dr. Panigrahi's responsibilities include establishing and leading Sucampo's medical science liaison department; leading medical message development, publications planning, key opinion leader development; and providing advice on clinical trial design and development.

Dr. Panigrahi joins Sucampo from Provision Pharmaceutical Consulting. He received both an M.D. and an M.S. in medical sciences from Hahnemann School of Medicine.

Silvia Taylor has joined Sucampo as senior VP of investor relations, public relations, and corporate communications. Ms. Taylor comes to Sucampo from MedImmune, where she held positions of increasing responsibility, among them senior director of marketing, RSV franchise and senior director of marketing, global influenza franchise. She received an MBA in marketing and management from Columbia Business School.



► BIOTECHNOLOGY POOL

Dr. Samuel BRODER

XCOVERY ADDS CLINICAL STRATEGIST



Xcovery, a clinical-stage biotech company focused on the development of next-generation targeted therapeutics for cancer, has named Samuel Broder, M.D., senior scientific and clinical strategist. Dr. Broder was previously executive VP for medical affairs and chief medical officer at Celera. He received an M.D. from the University of Michigan Medical School.

► BIOPHARMACEUTICAL POOL

Dr. Steven BENNER

CELL THERAPEUTICS TAPS FORMER ONCOMED EXECUTIVE AS MEDICAL CHIEF

Cell Therapeutics, a biopharmaceutical company



focused on translating science into novel cancer therapies, has named Steven Benner, M.D., executive VP and chief medical officer. Dr. Benner was previously senior VP and chief medical officer at OncoMed.

David COLPMAN

SHIRE APPOINTS GLOBAL BUSINESS DEVELOPMENT HEAD



Global specialty biopharmaceutical company Shire has promoted Senior VP David Colpman to lead its global business development team. Mr. Colpman has been with Shire for 12 years.

Dr. Bela DENES

CLARUS THERAPEUTICS NAMES MEDICAL CHIEF



Clarus Therapeutics has named Bela Denes, M.D., chief medical officer. Dr. Denes was most recently senior medical director at Abbott Laboratories. He completed medical school and residency training at Washington University in St. Louis.

Clarus is a privately held biopharmaceutical company focused on the development and commercialization of the oral testosterone replacement product CLR-610.

Allene DIAZ

Rami LEVIN

Evan LIPPMAN

Craig MILLIAN

EMD SERONO STRENGTHENS LEADERSHIP ROSTER



Biopharmaceutical firm EMD Serono, a U.S.-based subsidiary of Germany's Merck KGaA, has announced additions and promotions to its senior executive team.

Allene Diaz has been promoted to senior VP, head of U.S. oncology. Since joining EMD Serono in 2008, Ms. Diaz has served as VP, oncology marketing and as acting head, global strategic planning.

Rami Levin has been appointed VP of marketing, neurodegenerative diseases and rheumatology. Mr. Levin has been with Merck Serono since 1998, most recently as chairman and managing director of Merck AB in Sweden and Iceland.



Evan Lippman has joined EMD Serono as senior VP of neurodegenerative diseases and rheumatology. Mr. Lippman was most recently executive director of AstraZeneca's Crestor brand. He holds an MBA from Cornell University.

Craig Millian has been named senior VP and head of EMD Serono's U.S. fertility, metabolic endocrinology, and HIV franchise after taking over this role on an ad-interim basis earlier this year. Before that, Mr. Millian served as VP of endocrinology marketing. He received an MBA from New York University.

Dr. Darlene HORTON

NILE THERAPEUTICS APPOINTS MEDICAL CHIEF



Nile Therapeutics, a biopharma company that develops novel therapeutics for heart failure patients, has named Darlene Horton, M.D., chief medical officer. Dr. Horton was previously chief medical officer of Itero Biopharmaceuticals.

Dr. Frank HSU

ZYNGENIA NAMES MEDICAL CHIEF



Zyngenia, a biopharmaceutical company developing next-generation multispecific antibody-based drugs in oncology and immunology, has appointed Frank Hsu, M.D., chief medical officer. Dr. Hsu is a medical oncologist and immunologist with deep academic and industry clinical research experience who most recently served as senior medical director in Genzyme's transplant and oncology division. He received a medical degree from Harvard Medical School as part of the Health, Science and Technology (Harvard-MIT) program.

Dr. Néstor MOLFINO

KALOBIOS SELECTS FORMER MEDIMMUNE VP AS MEDICAL CHIEF



KaloBios Pharmaceuticals, a biopharma company developing proprietary monoclonal antibodies designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases, has appointed Néstor Molfino, M.D., chief medical officer. Dr. Molfino was previously VP, clinical development and respiratory therapeutic area head, at MedImmune. He received an M.D. from the Universidad Nacional de Rosario in Argentina and an M.Sci. degree from the University of Toronto/Mount Sinai Research Institute.

Henry RATH**AMGEN DIRECTOR JOINS CATABASIS**

Catabasis Pharmaceuticals, a clinical-stage biopharma company developing medicines for the treatment of inflammatory and metabolic diseases, has named Henry Rath VP, business development. Mr. Rath previously served as the executive director of corporate development at Amgen. He received an MBA from the Wharton School of the University of Pennsylvania.

▶ DIAGNOSTIC POOL**Kevin HARTER****SALADAX APPOINTS CEO**

Kevin Harter has been named Saladax Biomedical's president and CEO. Mr. Harter has been serving as interim CEO since January 2012. He received an MBA from Pennsylvania State University. Saladax is a privately held company developing and commercializing novel diagnostic assays for the practical delivery of personalized medicine.

▶ EMERGING POOL**Dr. Paul LAIKIND****VIACYTE ANNOUNCES LEADERSHIP TRANSITION**

ViaCyte, a preclinical cell therapy company developing a novel cell therapy product for the treatment of insulin dependent diabetes, has appointed Paul Laikind, Ph.D., president and CEO. Allan Robins, Ph.D., who had been serving as acting CEO, continues in his role as VP and chief technology officer.

Most recently, Dr. Laikind served as chief business officer and senior VP of business development for the Sanford-Burnham Medical Research Institute. He received a Ph.D. in biochemistry from the University of California, San Diego.

▶ REGULATORY POOL**Dr. Gerald DAL PAN****FDA CDER APPOINTS OSE DIRECTOR**

Gerald Dal Pan, M.D., has been appointed perma-



nent director of the newly reorganized Office of Surveillance and Epidemiology (OSE) within the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER). OSE plays a critical role in monitoring and safeguarding drugs once they are on the market.

As OSE director since 2005 and acting director of the reorganized OSE super-office since June 2011, Dr. Dal Pan has been instrumental in conceptualizing and managing CDER's postmarket drug safety and risk assessment programs.

▶ AGENCY POOL**Jose GONZALEZ****Greg NAMI
Ernie TORRES****ABELSONTAYLOR EXPANDS ART TEAM**

Independent healthcare advertising agency AbelsonTaylor has appointed three people in its art department.



Jose Gonzalez has been promoted to senior art director, from art director. Mr. Gonzalez is working on products in the cardiovascular and oncology areas.



Greg Nami has been promoted to art director from associate art director, working across all accounts. Since joining AbelsonTaylor in 2008, Mr. Nami has handled both professional and consumer materials for multiple brands, including products for the



treatment of hypertension, angina, infection, women's health, and neonatal respiratory distress syndrome.

Ernie Torres has joined AbelsonTaylor as art director. Mr. Torres was most recently art director/creative manager for CorbettAccel Healthcare Group's clinical trials programs.

**Paul HAGOPIAN
Jonathan PEISCHL
Dr. Adena SVINGOS****EXECUTIVE ADDITIONS AT GIANT CREATIVE/STRATEGY**

Full-service independent healthcare advertising agency Giant Creative/Strategy has added three VPs to its leadership team.

Paul Hagopian has been named



senior VP, managing group director. Mr. Hagopian was previously senior VP at Cline, Davis & Mann.



Jonathan Peischl has joined Giant as senior VP, director of innovation and digital marketing. Mr. Peischl was most recently senior VP, creative director, at Kane & Finkel Healthcare Communications.

Adena Svingos, Ph.D., has been appointed senior VP, medical director. Dr. Svingos has more than 15 years of academic and healthcare marketing experience.

**Bryan HILL
Will REESE****CADIENT REALIGNS KEY EXECUTIVE DUTIES**

Cadient Group, a life sciences-focused marketing agency, has announced two promotions within its leadership team.



Bryan Hill has been promoted to chief technology officer, from senior VP for global technology services. Mr. Hill is playing an expanded role in developing the agency's technology solutions and advancing digital delivery capabilities in mobile and social.

Will Reese has been promoted to managing partner, from chief innovation officer. Mr. Reese's responsibilities include overseeing Cadient's strategic consultancy and managing the agency's strategic, creative, media, and insights and analytics teams.

**Tom JONES
Jennifer LAWSON****MAKOVSKY CONTINUES HEALTH PRACTICE EXPANSION**

Makovsky + Company has promoted Tom Jones to senior VP of its health practice. Mr. Jones has been with Makovsky Health since January 2011.



Jennifer Lawson has joined Makovsky Health as account supervisor. Ms. Lawson's eight years of previous healthcare communications experience include positions with Feinstein Kean Healthcare, JFK Communications, and GCI Group (now GCI Health).

**Meredith MANDATO
Amanda MERCED****MCS HEALTHCARE BOLSTERS ACCOUNTS TEAM**

MCS Healthcare Public Relations has promoted two members of its accounts group. Meredith



Mandato has been promoted to senior account executive, from account executive. Ms. Mandato provides support for the development and implementation of corporate communications and media relations campaigns for clients.



Amanda Merced has been elevated to account supervisor, from senior account executive.

Ms. Merced's responsibilities include the development of strategic and creative solutions that match clients' communication goals, as well as the coordination of social media programs.

Augé REICHENBERG

ROSETTA STRENGTHENS CREATIVE TEAM



Digital and direct interactive agency Rosetta, an independent brand in the Publicis Groupe of global agencies, has named Augé Reichenberg executive creative director for healthcare. Ms. Reichenberg works on a number of key accounts within the agency's healthcare vertical. She was most recently executive VP, group creative director, for Drafftcb New York.

Phil SCOTT

GSW APPOINTS MARKETING VETERAN



Global healthcare advertising agency GSW Worldwide, an inVentiv health company, has named Phil Scott executive VP, innovation and product marketing.

Mr. Scott joins GSW with more than 20 years of senior level experience in consumer packaged goods and consumer electronics marketing and sales, primarily at Eastman Kodak and Bank One (now Chase). In his most recent role at Eastman Kodak, Mr. Scott was responsible for strategic business planning, product generation, product management, marketing communications, and brand management for the Kodak EasyShare, Pulse, PlaySport and Essentials businesses.

► **CONSULTING POOL**

Jim BURKE
Laszlo FABRICZI
Gaurav SURI

ALSCG EXPANDS CONTRACTING AND PRICING SOLUTIONS PRACTICE
Management and technology consultancy Alliance



Life Sciences Consulting Group (ALSCG) has expanded several leadership roles in its contracting and pricing solutions practice.



Jim Burke, formerly VP of the practice, has been promoted to senior VP of contracting and pricing solutions.



Mr. Burke continues to consult directly with clients and assist with oversight of large engagements and plays a larger role in strategic planning for the firm.

Laszlo Fabriczi, has been promoted to VP, from director. Mr. Fabriczi is responsible for overall solution delivery, including establishing and maintaining the ALSCG delivery methodology, managing and growing the company knowledge base, and managing employee development and training.

Gaurav Suri has been elevated to VP, from director.

Mr. Suri is responsible for overall business development within the contracting and pricing solutions practice, including coordination of business development activities between sales and the practice directors, exploring and developing new solution offerings, and ensuring that the company maintains its partnerships and presence across the industry.

Chris WRIGHT

ZS ASSOCIATES PROMOTES MANAGING DIRECTOR



Global sales and marketing consulting firm ZS Associates has selected Chris Wright as managing director.

Since joining ZS Associates in 1989, Mr. Wright has held several leadership roles at the firm, most recently serving as a regional managing principal of North America and managing principal of the firm's global pharmaceuticals practice.

He received an MBA with honors from the Kellogg School of Management, Northwestern University.

► **CRO POOL**

Dr. James CARLSON
John POTTIER
CETERO RESEARCH RENAMED PRACS INSTITUTE

James Carlson, Pharm.D., has been named CEO of Pracs Institute, formerly known as Cetero Research.



Dr. Carlson has more than 30 years of experience in early phase research and co-founded and served as CEO of a legacy operation of Cetero Research.



In other moves, John Pottier has been named executive VP, business development.

Mr. Pottier joins Pracs from Worldwide Clinical Trials.

Dr. Steve STREET

NEW VP JOINS COVANCE IN U.K.



Global clinical research organization Covance has appointed Steve Street, Ph.D., global vice president and general manager. Based in Harrowgate, United Kingdom, Dr. Street is responsible for overseeing Covance's worldwide safety assessment and pharmaceutical chemistry services.

Dr. Street was most recently VP and head of two global R&D units – the Research Centers of Emphasis and Continuous Improvement – at Pfizer. He received a doctorate from Leeds University in the United Kingdom.

► **MEDIA POOL**

Tracy CHAPMAN
Andy JACOBSON
Laura KLEIN
Orlando REECE
Ju-Don ROBERTS
Scott WOLF

EVERYDAY HEALTH EXPANDS SALES ORGANIZATION, INTEGRATED OFFERINGS



Digital health information company Everyday Health has made a number of additions and promotions to its senior management team.



Tracy Chapman has joined Everyday Health as VP, consumer insights. Ms. Chapman leads the new Everyday Health Insights Lab unit to provide intelligence on shared consumers with clients and look at behaviors on and beyond the Web. She was most recently a principal at Just Ask a Woman and is the co-author of What She's Not Telling You: Why Women Hide the Whole Truth and What Marketers Can Do About It.

Andy Jacobson has been appointed VP, sales, responsible for leading Everyday Health's emerging and inside sales teams. Mr. Jacobson most recently



served as VP of digital sales at Gannett.

Laura Klein has been promoted to executive VP, sales, from senior VP, sales. Ms. Klein has been with Everyday Health since 2007.



Orlando Reece has joined the firm as VP, head of broadcast and digital video sales.

Mr. Reece has more than 20 years of experience within broadcast networks, cable networks, and digital media companies, most recently with Grab Networks.



Ju-Don Roberts has been promoted to general manager and senior VP, overseeing the Web, mobile, social, video, and product strategies for EverydayHealth.com. Ms. Roberts joined Everyday Health in July 2011 as VP and editor in chief, news and audience development.



Scott Wolf has been promoted to chief sales officer from executive VP, sales. Mr. Wolf joined Everyday Health in 2005 to help launch EverydayHealth.com.

Cavan REDMOND

WEBMD TAPS FORMER PFIZER PRESIDENT AS CEO



Cavan Redmond has joined health information services provider WebMD Health as CEO. Mr. Redmond most recently served as Pfizer's group president, animal health, consumer health-care and corporate strategy.

He earned a master of administrative science from The Johns Hopkins University, where he also completed a postgraduate fellowship in organizational change management.

▶ SERVICE POOL

Richard BENDIS

BIOHEALTH INNOVATION APPOINTS CHIEF EXECUTIVE



BioHealth Innovation (BHI) has named former Interim CEO Richard Bendis as president and CEO.

Mr. Bendis was previously the founding president and CEO of Innovation America.

BHI is a regional private-public partnership focusing on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Central Maryland.

Dale BENNER

FORMER IMS HEALTH DIRECTOR JOINS TGAS ADVISORS



Benchmarking and advisory services company TGaS Advisors, a division of KnowledgePoint360, has appointed Dale Benner director, solutions management.

Mr. Benner was most recently director, U.S. commercial planning and implementation at IMS Health. He earned an MBA from Regis University.

Mark ENGELHART



NEW COMMERCIAL CHIEF AT ACM GLOBAL

ACM Global Central Lab has appointed Mark Engelhart chief commercial officer, responsible for leading ACM Global's business development; proposals; and contracts, marketing, and sales activities worldwide.

Mr. Engelhart was most recently chief commercial officer at Cryoport.

Joseph MASTRACCHIO



DMD NAMES EXECUTIVE CONSULTANT

DMD, a company that connects health-care practitioners to professional information sources through comprehensive database deployment services, has appointed Joseph Mastrocchio as an executive consultant.

With more than 40 years in the pharmaceutical and healthcare marketing industry, Mr. Mastrocchio offers his expertise in pharmaceutical sales, critical strategic thinking, medical communications, and marketing solutions to increase the market penetration and productivity of DMD and its clients.

Dr. Laura PARKS



DSM PROMOTES PRESIDENT

DSM Pharmaceutical Products, a U.S.-based business group of Dutch life-sciences and material-sciences firm Royal DSM N.V., has promoted Laura Parks, Ph.D., president and business unit director of DSM's finished dosage business. Dr. Parks was previously DSM's senior VP of marketing and sales. She holds a Ph.D. in food science from the University of Georgia.

David WETHERELL

BURRILL ADDS TO HEALTHCARE FUND



Burrill & Company, a diversified global financial services firm focused on the life-sciences industry, has named David Wetherell president and chief operating officer of Burrill's healthcare venture and related private equity funds. Mr. Wetherell joined Burrill at the beginning of 2012.

▶ TECHNOLOGY POOL

Anthony COSTELLO Dr. Steve CUMMINGS

MYTRUS APPOINTS EXECUTIVES



Mytrus, a clinical technology and services company for medical and pharmaceutical research, has appointed Anthony Costello CEO. Mr. Costello is one of the founding members of Mytrus and previously served as its chief operating officer.



Mr. Costello succeeds Chairman Steve Cummings, M.D., who has been named to the additional post of chief scientific officer.

Bob HARRELL

APPATURE SELECTS HEALTHCARE MARKETING VP



Appature, a software-as-a-service (SaaS) provider for life sciences, has appointed Bob Harrell VP of marketing, healthcare. Mr. Harrell was previously director of integrated marketing for Shire Pharmaceuticals.

Anu SHARMA

SIMULATIONS PLUS STRENGTHENS CHEMINFORMATICS EXPERTISE



Simulations Plus, a provider of simulation and modeling software for pharmaceutical discovery and development, has named Anu Sharma senior sales and marketing manager, focusing on cheminformatics products.

Ms. Sharma has a strong background in both pharmaceutical chemistry and software sales and holds a master's degree in chemistry as well as an MBA. ^{PV}



USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0912-TalentPool



▶ PHARMACEUTICAL POOL

Katrina CHURCH
James HARTMAN

MERZ APPOINTS VPS AT U.S. AFFILIATE

Merz Inc., the U.S. affiliate of Frankfurt-based Merz Pharma Group, has promoted Katrina Church to VP, chief compliance officer. Ms. Church joined Merz in November 2009 and has more than 20 years of legal experience in various areas, including private legal practice and in-house corporate counsel positions. She holds a J.D. from the New York University School of Law.

James Hartman has been appointed VP, medical dermatology, responsible for Merz's medical and OTC/OTX dermatology business unit. Mr. Hartman was previously VP, global marketing and business development, at Obagi Medical Products.

▶ BIOTECHNOLOGY POOL

Dr. John CHIPLIN

NEW CEO AT POLYNOMA

Polynoma, an oncology-focused biotechnology company within Hong Kong-based CK Life Sciences, has named John Chiplotin, Ph.D., CEO. Dr. Chiplotin brings more than 25 years of biopharmaceutical and healthcare-related experience to Polynoma, most recently as founding CEO of Arana Therapeutics.

Robert HOUSLER JR.

FORMER STRYKER SPINE SALES DIRECTOR JOINS INVIVO

Robert Housler has joined InVivo Therapeutics Holdings as VP of business development. Mr. Housler is responsible for InVivo's effort to establish strategic relationships and partnerships, including targeted licensing of the company's polymer technologies to neurotrauma industry leaders.

Mr. Housler was previously director of strategic sales at Stryker Spine. He received an MBA from the State University of New York at Buffalo.

Dr. Scott PETERSON

ONCOTHYREON PROMOTES SCIENTIFIC CHIEF

Oncothyreon, a biotech company specializing in the development of products for the treatment of cancer, has promoted Scott Peterson, Ph.D., to chief scientific officer. Dr. Peterson joined Oncothyreon in August 2009 as VP, clinical development. He received a Ph.D. in chemistry from the University of Colorado Boulder.

▶ BIOPHARMACEUTICAL POOL

Dr. Laurent FISCHER

FORMER OCERA CHIEF JOINS JENNEREX AS CEO

Jennerex, a private clinical-stage biotherapeutics company focused on the development and commercialization of targeted oncolytic immunotherapy products for cancer, has named Laurent Fischer, M.D., president and CEO. Dr. Fischer succeeds Interim CEO Ken Newport, who continues as a Jennerex board member.

Dr. Fischer has 20 years of drug development and commercialization experience in the biopharmaceutical industry, most recently as president and CEO of Ocera Therapeutics. He received a medical degree from the Geneva Medical School in Switzerland.

Dr. Karin HEHENBERGER

CORONADO BIOSCIENCES PROMOTES MEDICAL CHIEF

Coronado Biosciences, a biopharmaceutical company focused on the development of immunotherapy agents for the treatment of autoimmune diseases and cancer, has promoted Karin Hehenberger, M.D., Ph.D., to executive VP and chief medical officer, from senior VP of scientific affairs. Dr. Hehenberger is responsible for providing strategic scientific input and oversight of the company's clinical development programs and medical affairs, which expands upon her previous role of broadening the scope of proof-of-concept trials in autoimmune diseases for lead compound TSO. She holds both an M.D. and a Ph.D. from the Karolinska Institute in Stockholm.

Dr. Jonathan JAFFE

ANTARES NAMES CLINICAL DEVELOPMENT VP

Antares Pharma, a biopharma company focused on self-injection pharmaceutical products and topical gel-based medicine, has appointed Jonathan Jaffe, M.D., VP of clinical development. Before joining Antares, Dr. Jaffe served on a consulting basis for PharmaNet-i3. He received an M.D. from the Jefferson Medical College of Thomas Jefferson University.

Robert PEREZ
Thomas ROLLINS

CUBIST PHARMACEUTICALS ANNOUNCES SENIOR EXECUTIVE APPOINTMENTS

Cubist Pharmaceuticals has promoted Robert Perez to president and chief operating officer from executive VP and chief operating officer. Mr. Perez first joined Cubist in 2003 as senior VP of Cubist's sales and marketing team.

In addition, Thomas Rollins has been appointed

senior VP of program and portfolio management. Mr. Rollins joins Cubist from Sunovion Pharmaceuticals, where he was senior VP of program management and R&D planning.

Cubist is a biopharma company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment.

▶ SPECIALTY POOL

Louis FERRARI

SAVIENT PHARMACEUTICALS NAMES CEO

Savient Pharmaceuticals has promoted Louis Ferrari to president and CEO from executive VP, president North American commercial operations. Mr. Ferrari succeeds Interim CEO David Norton, who continues as a member of Savient's board of directors. Mr. Ferrari received an MBA from Adelphi University.

Savient is a specialty biopharmaceutical company focused on developing and commercializing Krystexxa for the treatment of chronic gout in adult patients refractory to conventional therapy.

▶ AGENCY POOL

John MONACCHIO

AXIOM ADDS BUSINESS DEVELOPMENT DIRECTOR

Axiom, a member of the Huntsworth Health group of agencies, has named John Monacchio director of business development. Mr. Monacchio joins Axiom following a 20-year career at Johnson & Johnson, where he worked in the Ortho McNeil Pharmaceuticals division.

▶ CRO POOL

John CAPICCHIONI

AKESIS ANNOUNCES LEADERSHIP CHANGE

Akesis, a contract research firm specializing in Phase II-IV clinical dermatology services and regulatory affairs consulting, has named John Capicchioni president. Mr. Capicchioni was previously senior VP of business development for global early clinical and bioanalytical research at MDS Pharma Services.

Celine HOUSER
Dr. Cara PENDERGRASS
Philip RAUH

CLINTARA BOLSTERS LEADERSHIP

Clintara, a privately held company that works with pharmaceutical companies and CROs to optimize outcomes of central nervous system clinical studies, has announced a number of additions and promotions to its executive team.

Celine Houser has been promoted to executive director, program development, working with clients on program design and the initial phase of program implementation.

As VP of clinical operations, Cara Pendergrass, Ph.D., manages a clinical team that includes more than 35 prominent CNS clinicians in the Americas, Middle East and North Africa, and Asia Pacific regions. Dr. Pendergrass received an M.S. and a Ph.D. in clinical psychology with a specialization in neuropsychology from Rosalind Franklin University of Medicine and Science.

Philip Rauh has been named VP, client services, focusing on implementing the delivery of the Clintara platform to clients in an effective and timely manner. Mr. Rauh earned an M.A. of international economics with emphasis on quantitative analysis from the Graduate Institute of International Studies of the University of Geneva in Switzerland.

▶ SERVICE POOL

Dick **ELLIOTT**
Garth **ELLIOTT**
Kirk **ELLIOTT**
Cindy **MORRISON**
Terry **NUGENT**
Kristy **VANDERPLOW**

MMS ANNOUNCES SUCCESSION MOVES

Medical Marketing Service (MMS), a provider of healthcare lists and email marketing services, has announced a number of staff transitions.

Dick Elliott has assumed the role of chairman/CEO after more than 40 years serving MMS in a number of increasingly responsible positions culminating in the presidency.

Garth Elliott has assumed responsibility for day-to-day operations of MMS as president/COO. Kirk Elliott has been promoted to chief information officer after more than two decades of service to MMS in the operational area.

Cindy Morrison has transitioned to the role of email marketing manager, with responsibilities including the review of email creative work and report trending. Terry Nugent has been promoted to executive VP of sales and marketing.

Kristy Vanderplow has joined MMS to manage its customer service department. Ms. Vanderplow has more than two decades of experience meeting the mailing list, email marketing services, and data needs of healthcare marketers.

Dr. Laura JONES

NEW REGULATORY AFFAIRS VP AT AVRIO BIOPHARMACEUTICALS

Avrio Biopharmaceuticals, a global cGMP contract aseptic manufacturing organization, has appointed Laura Jones, Ph.D., VP of quality and regulatory affairs. Dr. Jones is responsible for overseeing Avrio's quality and regulatory compliance systems.


Dr. Jones was previously quality assurance director for Bayer HealthCare. She holds a Ph.D. in microbiology from Louisiana State University, an M.S. in regulatory affairs and advanced regulatory affairs certification from San Diego State University, an MBA in management/marketing from the University of Wisconsin-Madison, and a J.D. from the American College of Law.

▶ TECHNOLOGY POOL

William NELLIGAN

FORMER IMS EXECUTIVE JOINS SYMPHONY HEALTH AS CEO

Symphony Health Solutions, a provider of high-value data, analytics, and technology-based solutions for the life-sciences industry, has appointed William Nelligan CEO. Mr. Nelligan joins Symphony Health Solutions after more than a decade with IMS Health, where he most recently served as president, U.S. and Americas.

Symphony Health Solutions was formed in May 2012 by the Symphony Technology Group (STG) through the combination of four complementary healthcare insight companies: AlphaDetail, ImpactRx, Source Healthcare Analytics, and TargetRx. 

Expanded Access Programs for New Therapies

Providing Patients Access to Drugs Prior to Approval While Obtaining Broad Exposure and Safety Data

October 3-4, 2012
Charlotte, NC

“Implement

new strategies for running Expanded Access Programs, and gain insight into how to reduce risks and Maximize positive results.”

Given the rising demand for life saving treatments in the pharmaceutical and biotechnology industry, Expanded Access Programs have allowed companies to provide investigational new drugs and devices to patients in need. Therefore, it is crucial for companies to overcome the regulatory challenges and liabilities within these programs to ensure successful / optimal results.



Attending this Premier marcus evans Conference will Enable You to:

- **Gain** an understanding of Expanded Access Programs and their future in the pharmaceutical and biotechnology industry
- **Investigate** the life saving benefits Expanded Access Programs have on patients worldwide
- **Execute** Expanded Access Programs while minimizing risks and financial implications
- **Understand** regulations that must be implemented when running Expanded Access Programs both in the United States and Globally
- **Prepare** for challenges that arise when implementing Expanded Access Programs
- **Grasp** the importance of patient advocacy when running Expanded Access Programs

Who Should Attend:

marcus evans invites Heads, Vice Presidents, Directors with responsibilities or involvement in the following areas:

- Medical Affairs
- Regulatory Affairs
- Clinical Development
- Clinical Affairs
- Scientific Affairs
- Patient Advocacy

Scan Here for More Information on this Conference



Silver Sponsor:

idis
Partner for life™

Media Partners:

BioCentury™

phamaphorum™
The Journal of the Pharmaceutical Industry

BioPortfolio

Medical News TODAY

RAPS REGULATORY AFFAIRS PROFESSIONALS SOCIETY
Making better healthcare products possible™

www.PharmCast.com
- Pharmaceutical Internet -

Pharma VOICE

marcusevans conferences

For More Information,
Please Contact: Robin Yegelwel
T: 312-540-3000 ext 6483
E: robyn@marcusevansch.com